alemán - B2.2 - Israelische Studie: Coronavirus-Variante kann BioNTech/Pfizer-Impfung überwinden

Study Notes

A study by Israeli researchers suggests that vaccinated individuals have a higher risk of getting infected with the South African COVID-19 variant than unvaccinated individuals.
Pfizer had previously advertised the strong efficacy of its vaccine.
There are still many uncertainties in the fight against coronavirus, particularly with the emergence of the British and South African variants.
Laboratory studies had already hinted that the South African variant could break through the protection of the Pfizer vaccine, but the study on real subjects confirmed this.
The study was conducted by the University of Tel Aviv in collaboration with Clalit, the largest Israeli health fund.
400 vaccinated individuals who tested positive for COVID-19 were compared to 400 unvaccinated individuals who also contracted the virus.
The South African variant has a higher likelihood of breaking through the vaccine's protection, even after two doses have been administered.
The prevalence of the South African variant is eight times higher in vaccinated individuals compared to unvaccinated individuals.
The study's results are limited due to the rarity of the South African variant in Israel.
The study was not intended to derive a general efficacy of the vaccine against any variant as it only examined individuals who had already tested positive for COVID-19.